Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
OncoSenX
AddedFeb 15, 2024
UpdatedJun 18, 2026
OncoSenX

OncoSenX

Seed

Seattle-based OncoSenX develops gene therapy for solid tumors using unique lipid nanoparticles and DNA.

HQ
Seattle, WA, US
Founded
2017
Overview
Compare
Fundraising
Employees
Website

OncoSenX, founded in Seattle, Washington, is a late-stage pre-clinical cancer company focused on developing next-generation gene therapies for solid tumors. The company employs a unique approach using Proteo-Lipid Vehicles (PLVs) and plasmid DNA to target cancer cells based on their transcriptional activity. OncoSenX’s core mission is to create more targeted cancer treatments with fewer side effects, aiming to revolutionize the field of oncology.

Notable figures affiliated with OncoSenX include experts in gene therapy and oncology, though specific names are not provided. The company has attracted significant interest from investors in the biotech sector. Key achievements include advancing their proprietary technology through pre-clinical stages, positioning themselves as innovators in targeted cancer therapy. OncoSenX's impact lies in its potential to offer more effective and less harmful treatment options for cancer patients.

OncoSenX - Similar Companies

OncoSpherix logo

OncoSpherix

oncospherix.com

Oncolix logo

Oncolix

OncXerna Therapeutics logo

OncXerna Therapeutics

oncxerna.com

Seneca Therapeutics logo

Seneca Therapeutics

OncoResponse logo

OncoResponse

OncoPrecision logo

OncoPrecision

oncoprecision.bio

Oncofactor logo

Oncofactor

oncofactor.com

OncoTrap logo

OncoTrap

Senex Biotechnology logo

Senex Biotechnology

senexbio.com

Nexosome Oncology logo

Nexosome Oncology

OncoMyx Therapeutics logo

OncoMyx Therapeutics

oncomyx.com

OncoNano Medicine logo

OncoNano Medicine

onconano.com

Western Oncolytics logo

Western Oncolytics

Oncolyze logo

Oncolyze

oncolyze.com

Traws Pharma logo

Traws Pharma

OncoSenX - Quick Facts

Who are OncoSenX's competitors?

Companies similar to OncoSenX include OncoSpherix, Oncolix, OncXerna Therapeutics and Seneca Therapeutics.

When was OncoSenX founded?

OncoSenX was founded in 2017.

Where is OncoSenX's headquarters located?

OncoSenX's headquarters is located in Seattle, WA, US.

How much has OncoSenX raised to-date?

As of Jan 29, 2021, OncoSenX has raised a total of $11.7M (USD).

How many employees does OncoSenX have?

OncoSenX has 14 employees as of Feb 5, 2024.

OncoSenX - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Software
Main Product
  • Gene Therapy
Tags
  • Biotech
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 5 more industry codes
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified